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Abstract
Background—Individualized pharmacotherapy requires identification of genetic variants
predictive of treatment response. In OPRM1, Asn40Asp has been reported to be predictive of
response to naltrexone treatment. Nevertheless, the in vitro function of the polymorphism remains
elusive and over 300 OPRM1 sequence variants have been identified to date. Therefore we used a
haplotype-based approach to capture information of other genetic variants that might predict
treatment response to naltrexone in the COMBINE Study.
Methods—5’ nuclease genotyping assays (TaqMan®) were applied for 10 SNPs. Five-locus
haplotypes in two OPRM1 haplotype blocks were assigned to Caucasian participants. The
relationship of the haplotypes to medication reflected by “good clinical outcome” was analyzed in
306 Caucasians treated without Combined Behavioral Intervention and with either naltrexone or
placebo.
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Results—A significant haplotype by medication interaction (P=0.03) was found in OPRM1
block 1. Naltrexone-treated alcoholics with haplotype AGCCC, the single haplotype carrying the
Asp40 allele had the highest percent of good clinical outcome. When interaction of genotypes at
each of the five loci comprising block 1 with medication was examined, only the Asn40/Asp40
and Asp40/Asp40 genotypes were found to significantly interact with naltrexone treatment. No
haplotype by medication interaction was documented in OPRM1 block 2.
Conclusions—Our haplotype-based approach confirms that the single OPRM1 locus predictive
of response to naltrexone treatment is Asn40Asp in exon 1. A substantial contribution of any other
OPRM1 genetic variant to interindividual variations in response to naltrexone treatment (at least in
terms of good clinical outcome) is not supported by our findings.
Keywords
OPRM1 Asn40Asp; naltrexone; treatment response; haplotype; good clinical outcome; haplotype
by medication interaction
Introduction
Effects of opioids are mediated through opioid receptors, mu, kappa, and delta, each a
seven-transmembrane domain G-protein coupled receptor (Inturrisi, 2002). Of the three
receptor subtypes, the opioid receptor mu 1 (OPRM1) is thought to account for the most of
the opioidergic effects (Kieffer and Gaveriaux-Ruff, 2002; Sora et al., 2001; Uhl et al.,
1999). OPRM1 is also the primary site of action of an endogenous opioid peptide, beta-
endorphin, released in response to ethanol (Gianoulakis and Barcomb, 1987), and a μ opioid
receptor antagonist, naltrexone (Volpicelli et al., 1992). Encoded by the OPRM1 gene
(6q24-q25; GeneID: 4988), OPRM1 is widely distributed in brain (Delfs et al., 1994). Over
300 OPRM1 genetic variants have been identified to date as a result of several re-sequencing
efforts that have included the 5’ and 3’ UTRs and flanking regions (Hoehe et al., 2000;
Ikeda et al., 2005).
Most abundant among the missense variants is Asn40Asp, which results from an A118G
transition (Bergen et al., 1997). The Asp40 allele frequency ranges from 0.10 to 0.15 in
Caucasians but the allele frequency is population specific; the average frequency of Asp40 is
0.04, 0.25–0.45, 0.16, 0.14 and 0.21 in African-Americans, East Asians, SW American
Indians, Hispanics and Ashkenazi Jews, respectively (Bergen et al., 1997; Bond et al., 1998;
Crowley et al., 2003; Gelernter et al., 1999; Hernandez-Avila et al., 2003).
Beta endorphin was reported to have 3-fold higher binding affinity at the Asp40 mutated
receptor than at the receptor encoded by the Asn40 allele. In addition, beta endorphin was
three times more potent at the Asp40 receptor in activating GIRK channels compared to the
receptor encoded by the Asn40 allele (Bond et al., 1998). By contrast, in two follow-up
studies, binding affinity for the variant receptor was not found to be different from that for
the normal receptor in COS cells (Befort et al., 2001), and no difference was documented
either in binding affinity or potency of beta-endorphin for the variant receptor in mammalian
HEK293 cells (Beyer et al., 2004). In a more recent study, the Asn40 mRNA was 1.5–2.5-
fold more abundant than the Asp40 mRNA in human autopsy brain tissue. Additionally, in
transfected CHO cells the Asp40 allele yielded 1.5-fold lower mRNA levels and more than
10-fold lower OPRM1 protein levels (Zhang et al., 2005).
The Asn40Asp polymorphism appears to have in vivo functional effects. Asp40 carriers
were found to have altered HPA activation resulting in higher cortisol levels both at baseline
and following infusion of the opioid receptor antagonist naloxone (Chong et al., 2006;
Hernandez-Avila et al., 2003; Wand et al., 2002) but less cortisol response to a social
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stressor (Chong et al., 2006). Due to its potential functional significance the polymorphism
has been extensively studied for association with addictions, with inconclusive results
(Bergen et al., 1997; Gelernter et al., 1999; Rommelspacher et al., 2001; Town et al., 1999).
Based on a recent meta-analysis the OPRM1 Asn40Asp polymorphism does not appear to
affect risk for substance dependence (Arias et al., 2006).
The utility of Asn40Asp as a predictor of treatment response in addictions has been
examined in four studies. Among smokers on short-term nicotine replacement therapy,
Asp40 carriers had higher rate of abstinence compared to Asn40/Asn40 homozygotes
(Lerman et al., 2004). Of treatment-seeking alcoholics prescribed naltrexone, those carrying
the Asp40 allele had significantly lower rates of relapse and took longer to resume heavy
drinking than Asn40/Asn40 homozygotes (Oslin et al., 2003). By contrast, in a post hoc
subgroup analysis no significant interactions were documented between any single
nucleotide polymorphisms (SNP) (including Asn40Asp) in any of three opioid receptor
genes and response to naltrexone treatment in the Veterans Affairs Cooperative Study
(Gelernter et al., 2007), a study in which naltrexone was not efficacious in the primary
analysis (Krystal et al., 2001). Finally, in a pre-planned pharmacogenetic ancillary study
(Goldman et al., 2005) within the larger COMBINE Study, alcoholics on naltrexone
carrying the Asp40 allele had increased percent days abstinent (PDA), decreased percent
heavy drinking days (PHDD) and higher rates of good clinical outcomes (GCO) compared
to Asn40/Asn40 alcoholics (Anton et al., 2008).
OPRM1 haplotypes were associated with substance dependence (Hoehe et al., 2000; Luo et
al., 2003) but not with severe opiod dependence (Crowley et al., 2003). More recently,
haplotypes composed of Asn40Asp and predominantly intronic SNPs were associated with
substance dependence in case/control studies (Zhang et al., 2006a; Zhang et al., 2006b) but
not in a family-based association study (Xuei et al., 2007). Considering the over 300 variants
in OPRM1, the paucity of clinical studies addressing OPRM1 haplotypes, the inconsistent
results regarding the in vitro function of Asn40Asp, and the inconclusive associations of
Asn40Asp with substance dependence and treatment response, we decided to use a
haplotype-based approach to capture more information of genetic variants that might predict
treatment response to naltrexone in the COMBINE Study population (Anton et al., 2006;
Goldman et al., 2005).
Materials and Methods
Subject Population
The subjects for this report were drawn from those 1383 individuals participating in the
federally funded COMBINE Study. Specific screening, selection and assessment methods,
detailed treatments, outcome measures and overall results can be found in a previous report
(Anton et al., 2006) Specific details of those that participated in the genetic sub-study of the
parent COMBINE Study can be found in a report focusing only on the relationship of the
Asp40 variant to naltrexone treatment response (Anton et al., 2008).
In essence, all subjects met DSM-IV criteria for alcohol dependence. After screening and 4
days of abstinence, subjects were randomized to receive naltrexone (100 mg/daily),
acamprosate (3 grams daily), both drugs, or their matching placebos for 16 weeks. All
subjects received medical management provided by health care professionals and half the
subjects received Combined Behavioral Intervention, a specialized counseling given by
addiction professionals. The subjects for this report are those that received naltrexone (with
or without acamprosate) or naltrexone placebo (with acamprosate or acamprosate placebo).
We limited the analysis to those who received the medical management condition without
Combined Behavioral Intervention since in our intent to treat analysis (Anton et al., 2006)
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and in our previous report of the Asp40 prediction of naltrexone response (Anton et al.,
2008) it was only this group of subjects in which naltrexone effects were observed. The
rationale for this, as detailed in our original report, was based on the interpretation of the
original finding that the CBI-treated subjects had no added benefit from naltrexone likely
due to a maximal treatment effect in this study population. We reasoned then that the
naltrexone (pharmacological) effect and subsequently the gene by naltrexone interaction
could only be observed in those that did not have the confound of receiving treatment (CBI)
that would obscure the observation of these effects. We utilized the same rationale in this
report to specifically examine the impact of other OPRM1 SNP’s and their combinations
(haplotypes) on the already established naltrexone effect in the medical management (MM)
group. The numbers in each condition, the population demographics and pre-study drinking
data and alcohol measures are given in Table 1.
Drinking was assessed over the course of the study with the timeline calendar follow-back
method (Sobell et al., 1972) which captures a daily estimate of drinking between visits. The
other outcome measure relevant for this report is the DrInC scale (Miller et al, 1995) which
captured the kind and level of alcohol related problems at the end of the study. Both
drinking quantity and frequency and level of alcohol problems were combined to construct
an a priori “good clinical outcome” measure based on previously published work (Zweben
and Cisler, 2003) and which captured a positive effect for naltrexone in the intent to treat
analysis (Anton et al., 2006) and in our original evaluation of the interaction of Asp40 allele
with naltrexone treatment (Anton et al., 2008). In this report we limit ourselves to this one,
easily interpretable, and consistent outcome measure. A good clinical outcome (GCO) is
defined as abstinent or moderate drinking without problems, a maximum of 11 (women) or
14 (men) drinks per week, with no more than 2 days on which more than 3 drinks (women)
or 4 drinks (men) were consumed and 3 or less alcohol-related problems endorsed on the
DrInC scale during the last 8 weeks of treatment. Subjects with missing values for this
variable were deemed as having experienced a poor (not good) clinical outcome.
SNP selection and genotyping
To date, ten splice variants of human OPRM1 have been identified with exons 1,2 and 3 as
constituent exons and differing by alternative splicing downstream from exon 3 (Bare et al.,
1994; Pan et al., 2005; Pasternak, 2004). Of these, the original version of the human OPRM1
gene (GenBank NM_000914.2) (Benson et al., 2007) containing four exons and spanning
79,864 bp has been the most extensively investigated, and was studied in the present work.
A schematic diagram of OPRM1 displaying the lengths of the exons and introns is shown in
Figure 1. Ten SNPs were selected from public databases including; the SNP database of the
National Center for Biotechnology Information (NCBI)
(http://www.ncbi.nlm.nih.gov/SNP/), the Applied Biosystems SNP database
(http://www.appliedbiosystems.com) and the International HapMap Project
(http://www.hapmap.org/). SNPs had minor allele frequencies of >0.05 in Caucasians and
were chosen to haplotype-tag the OPRM1 gene including 5’ regulatory and 3’ flanking
regions. The positions of the SNPs in OPRM1 and relative to the translation initiation site
(den Dunnen and Antonarakis, 2001) are given in Figure 1. To estimate the extent to which
the selected (tag) SNPs are representative (proxies) of non-genotyped OPRM1 SNPs
recorded in HapMap the program Tagger (http://www.broad.mit.edu/mpg/tagger/) was
employed (de Bakker et al., 2005).
Genotyping was performed with, 5’ nuclease (TaqMan®), a rapid and accurate method for
high throughput genotyping of SNPs (Livak, 1999; Shi et al., 1999). Genomic DNA was
extracted from peripheral blood mononuclear cells. The 5’ nuclease genotyping assay
(TaqMan®) combines polymerase chain reaction (PCR) amplification and sequence variant
detection into a single step (Livak, 1999; Shi et al., 1999). Locus-specific primers and
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fluorogenic allele-specific probes were designed and manufactured by Applied Biosystems
(ABI) (Foster City, CA, USA). Probes were fluorescently labeled either with 6-FAM or VIC
reporter dyes at the 5’ end. At the 3’ end was a non-fluorescent quencher (NFQ). The 5µl
reaction mixture consisted of 2.5µl of Taqman Universal Master Mix (ABI), 0.125µl of 40X
Assay Mix (ABI) (8µM detection probe for each allele, 36µM forward and reverse primer
each), and 10 ng of genomic DNA diluted in 2.375µl of Tris EDTA (TE) pH 8.0 (Quality
Biological, Inc; Gaithersburg, MD). Amplification was performed with an ABI Gene Amp®
PCR System 9700 using 384-well plates and the following amplification profile: 50°C for 2
min and 95°C for 10 min, followed by 40 cycles of 92°C for 15 s and 60°C for 1 min. After
amplification, endpoint fluorescence intensity was measured directly in the reaction plates,
by means of 7900 ABI Sequence Detector. Genotypes were determined using Sequence
Detection System Software Version 2.0 (ABI). Four genotyping signal clusters were
identified representing allele1/allele1 homozygotes, allele1/allele2 heterozygotes, allele2/
allele2 homozygotes and no-DNA-template control for each locus.
Genotyping accuracy was determined by replicate genotyping of at least 20% of the DNA
samples at each locus. Nucleotide substitution, discrepancy rate (ratio of the number of
discordant genotypes to the number of duplicates), genotyping completion rate (ratio of the
number of valid genotypes to the number of subjects genotyped (915)) at each locus and the
number of the duplicates at each locus are provided in Table 2 for the whole cohort.
HWE, LD and haplotype analysis
The program Haploview v3.32 (Barrett et al., 2005) was used to compute Hardy-Weinberg
equilibrium (HWE) for each locus, to estimate the extent of linkage disequilibrium (LD)
between each pair of markers and to determine the haplotype block structure. Haplotype
blocks were defined according to criteria proposed by Gabriel (Gabriel et al., 2002).
Genotype distributions for all SNPs were in HWE in the whole cohort and in the Caucasian
subgroup (Table 3). Haplotype pairs were assigned to each Caucasian participant using
PHASE v2.01 (Stephens and Donnelly, 2003). PHASE estimates the probabilities of all
likely pairs of haplotypes (diplotypes) assigned to each individual from genotype data. Of
these, diplotypes assigned with a probability of ≥ 0.80 were selected for further analysis. In
COMBINE OPRM1 block 1 and block 2, 668 and 667 Caucasian subjects respectively had a
diplotype assigned with a probability of ≥ 0.80. Non-Caucasian participants were excluded
from haplotype-based analysis. All genotyping, construction and assignment of haplotypes,
and data reporting were done blind to treatment assignment and outcome variables.
Statistical analysis
The statistical analysis was restricted to those 306 Caucasians (of the 687 Caucasians
genotyped) who received medical management without Combined Behavioral Intervention
and had haplotype data in at least one of the haplotype blocks. Baseline characteristics were
compared between the naltrexone and naltrexone placebo groups (Table 1). Categorical
variables are expressed as frequencies and percentages and equality tested using chi-squared
tests. Continuous variables are expressed as means and standard deviations and equality of
the means tested using two-sample t-tests. The baseline characteristics did not differ
significantly between the naltrexone and naltrexone placebo groups in any variables (all P
values were > 0.05).
The relationship of combinations of haplotypes with GCO was investigated separately for
each treatment group using a chi-squared test. Logistic regression was used to test whether
the relationships differed between the two treatment groups. In these models the GCO
indicator was used as the dependent variable and indicator variables for the haplotype
combinations, for treatment group and for combinations of treatment group by haplotype
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combinations as the independent variables. Because of the relatively small number of
participants, the models were not adjusted for baseline variables. The models were run
separately for block 1 and block 2 haplotype combinations (Table 7 and Table 10).
For block 1, each of the five SNPs in the block was investigated separately using a similar
approach to that described above for haplotypes. For each SNP, the proportion of
participants with a GCO was estimated separately for each combination of genotype and
treatment group. The interaction of genotype by treatment group on the GCO was tested
using logistic regression (Table 8). These analyses were then repeated for the four SNPs
other than the Asn40Asp locus in the group of participants who were Asn40/Asn40
homozygotes.
Results
Extent of SNP informativeness and haplotype blocks
The program Tagger (http://www.broad.mit.edu/mpg/tagger/) (de Bakker et al., 2005)
provided evidence that the 10 SNPs genotyped in COMBINE captured all the common
SNPs (MAF ≥ 5%) in OPRM1 (NM_000914.2) in HapMap (CEU) with an average r2 of
0.78 and 79% are captured with high r2 (≥ 0.8) using the aggressive (multimarker) approach.
LD analyses of the Caucasians subjects employing the program Haploview v3.32
demonstrated that the ten SNPs were distributed in two separate haplotype blocks (Figure 2).
SNPs 1–5 (SNP1 in the 5’regulatory region, SNP2 (Asn40Asp) in exon 1 and SNP3-5 in
intron 1) were in block 1 and SNP 6–10 (SNP6 in intron 2, SNP7-9 in intron 3 and SNP 10
in the downstream region) were in block 2.
Comparison of haplotypes in COMBINE and HapMap
We used a haplotype tagging approach and therefore expected that the configuration and
frequency of haplotypes constructed in the COMBINE dataset would be similar to those
available in HapMap. Indeed, the configurations of the major haplotypes (frequency ≥ 3%)
both in block 1 (Figure 3a) and block 2 (Figure 3b) are congruent with those of the major
haplotypes in the corresponding blocks of HapMap (Figure 3a and 3b). Likewise, the
frequencies of the major haplotypes in block 1 (Table 4) and block 2 (Table 5) are close to
the frequencies in HapMap Caucasians. Because many of HapMap haplotypes are minor
variations (low frequency daughter haplotypes) differing from a major haplotype by only
one or a few SNPs we grouped them on an objective basis. The five major haplotypes both
in the COMBINE Study block 1 and block 2 represent the collapse of HapMap daughter
haplotypes with mother haplotypes on a cladistic basis (Figure 3a and Figure 3b). The
haplotype cladograms in Figures 3a and 3b were constructed using HapCluster (available
from Qiaoping Yuan, (Zhou et al., submitted)) by hierarchical clustering of HapMap SNPs
within block regions. For the clustering, distances based on linkage disequilibrium (r2) are
used to group SNPs in linkage disequilibrium, and these distances are modified by the
frequencies of SNPs to give greater weight to abundant SNPs. Five tag SNPs in each block
were sufficient to detect the major HapMap haplotypes which can be derived from 44 and 49
SNPs in blocks one and two, respectively. Of note, the five major haplotypes in block 1
account for 96.9% of all detected haplotypes. Similarly, the five major haplotypes in block 2
account for 96.9% of all detected haplotypes. These findings are consistent with
observations that within human haplotype blocks most chromosomes are usually represented
by a relatively small number (three to five) of haplotypes (Gabriel et al., 2002). The
grouping of major haplotypes in the COMBINE Study block 1 and block 2 for haplotype-
based analyses is shown in Table 6.
Oroszi et al. Page 6













Relationship of haplotypes to medication in OPRM1 block 1
A significant haplotype by medication interaction (P=0.03) was found in patients treated
with naltrexone (Table 7). One haplotype combination (diplotype) accounted for most
individuals carrying the Asp40 allele, and this combination was AB. Only interactions of the
three most common diplotypes (AA, AB and AC) with medication were explored. Rare
diplotypes (BB, BC, CC, AO, BO, CO, OO) were omitted from the analysis. A higher
percentage (90.0%) of naltrexone-treated patients with the AB diplotype (one copy of
haplotype A plus the Asp40-carrying haplotype B) had GCO compared to naltrexone-treated
patients who did not carry haplotype B or placebo-treated patients of whatever diplotype
(Table 7). The percentage of placebo-treated patients with GCO did not differ significantly
among the diplotypes (Table 7). As a secondary analysis we also evaluated the effect on the
diplotypes on the percent of heavy drinking days over the course of the study. Those with
diplotypes AA, AB, AC treated with placebo had 15+/−3%, 16+/−4%, 17+/−3% heavy
drinking days (mean+/−SE) respectively compared to those same diplotypes treated with
naltrexone who had 11+/−2.0%, 5+/−3%, 9+/−2% heavy drinking days respectively. While
in the same direction as the GCO variable, with the Asp-40-containing diplotype (AB)
showing 45–55% less heavy drinking days compared to the other diplotypes when treated
with naltrexone, the interaction of medication and diplotype was not significant.
Relationship of each SNP comprising block 1 haplotypes to medication
Based on the significant haplotype by medication interaction in OPRM1 block 1, the intent
of this analysis was to evaluate whether any of the genotypes at the SNPs genotyped in
block 1 would show a naltrexone response over that expected by placebo (interaction of
medication with genotypes as shown in Table 8). A higher percent of patients had a GCO
among naltrexone-treated Asp40 carriers (87.1%) compared to naltrexone-treated Asn40
homozygotes (54.4%), placebo-treated Asp40 carriers (50%) and placebo treated Asn40
homozygotes (54.1%), a significant genotype by medication interaction (p=0.008).
Comparing naltrexone-treated Asp40 carriers to naltrexone-treated Asn40 homozygotes, the
odds ratio of having GCO was 6.28 (CI: 1.94–20.34) which is consistent with our previously
reported data (Anton et al., 2008). No significant genotype by medication interaction was
found at any of the other four SNPs (Table 8).
When only Asn40/Asn40 homozygotes were considered, thereby eliminating any main
effect of the Asp40 allele, no significant genotype by medication interaction was
documented for any of the other four SNPs (Table 9). Also, when Asp40/Asp40
homozygotes and Asp40/Asn40 heterozygotes were separately evaluated, there was again no
additive effect of any other Block 1 SNP (data not shown). Thus there is no significant
genotype by medication interaction of the Block 1 SNPs other than Asn40Asp.
Relationship of haplotypes to medication in OPRM1 block 2
The percentage of patients with GCO either in naltrexone- or placebo-treated groups did not
differ significantly among the three most common block 2 diplotypes (AA, AB and BB)
(Table 10). Other diplotypes with low frequencies (AO, BO, and OO) were omitted from the
analysis. Of note, differences in the percentage of patients with GCO in the naltrexone group
that are apparently significant (Table 10) are again due to the Asp40 allele, found in block 1.
This is probably due to extended linkage disequilibrium across the whole OPRM1 region,
with a tendency of the Asp40 allele to occur on the Block 2 “A” haplotype background. Of
the 64 subjects on naltrexone with the block 2 AA diplotype, 34.4% had at least one copy of
the Asp40 allele whereas among 70 subjects with the AB and BB diplotypes only 10.0%
carried the Asp40 allele. These percentages differ significantly (p<0.0008).
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The configuration and frequency of OPRM1 haplotypes in 685 Caucasians studied in the
COMBINE Study clinical trial are consistent with HapMap reference haplotypes derived
from 90 Caucasian subjects (CEU, Utah residents with a Northern and Western European
ancestry). In addition, evidence has been provided for a haplotype by medication interaction
in alcoholics treated with naltrexone. A significantly higher percentage of natrexone-treated
patients carrying the Block 1 haplotype AGCCC had GCO as compared to patients with
other diplotypes (haplotype combinations) or patients treated with placebo. The
distinguishing feature of this haplotype is the Asp40 allele, at position 2. No significant
interaction was found between any of the other major block 1 haplotypes (frequency ≥ 3%)
and medication. Also, in OPRM1 block 2 none of the five major haplotypes had any
significant effect on percentage of patients with GCO in either treatment group.
Despite the diversity of haplotypes representing Block 1, with five major haplotypes having
frequency ≥ 3%, only the AGCCC haplotype carries the Asp40 allele. As mentioned above
Asp40 has been shown to be predictive of response to naltrexone treatment in alcoholics by
ourselves and at least one other group, (Anton et al., 2008; Oslin et al., 2003) and evidence
has been provided for the in vitro and in vivo functionality of this missense variant. It should
also be noted that in our original report (Anton et. al, 2008) we presented data showing that
the Asp40 allele did not confer different medication compliance and/or adverse event
profiles, strengthening the specific primary therapeutic significance of this specific
polymorphism. We did not repeat that analysis for the haplotypes or diplotypes since no
other alleleic SNP or combination of SNPs was associated with good treatment response.
Hence, we hypothesize that Asp40 is likely to account for all of haplotype by medication
effect observed for block 1 haplotypes. In support of this hypothesis, when interaction of
genotypes at each of the five loci comprising block 1 with medication was examined, only
the Asn40/Asp40 and Asp40/Asp40 genotypes were found to significantly interact with
naltrexone treatment resulting in higher percent of patients with GCO. No significant
genotype by medication interaction was seen at any other locus in OPRM1 block 1 in our
study. Of importance, the OPRM1 block 1 haplotype is at least 44-kb in size, extending up
to 11.6 kb upstream of the 5’ end of OPRM1 and including the human OPRM1 promoter
region (Borner et al., 2002; Borner et al., 2004; Kraus et al., 2001). At least 37 genetic
variants (mainly SNPs) have been identified in the 5’ flanking region of the human OPRM1
to date (Hoehe et al., 2000; Ikeda et al., 2005) and a few of them (−1320A/G, −995C/A and
−554G/A) have been reported to be functional at least in vitro (Bayerer et al., 2007; Kraus et
al., 2001). Despite these reports, none of the major haplotypes in block 1 covering the
promoter region was found to interact with medication in the COMBINE Study sample
except the one carrying Asp40. Therefore it remains possible, but seems unlikely, that any of
these other genetic variants in the promoter or 5’UTR of OPRM1 would be predictive of, or
would have significant impact on, naltrexone treatment response.
Of note, though the most extensively investigated nonsynonymous variant in exon 1 is
generally (including our study) referred to as Asn40Asp (A118G) as described originally
(Bergen et al., 1997) this designation is no longer available in any of the public databases
(NCBI, HapMap, ABI), because of an understanding that the OPRM1 protein can contain an
additional 62 amino acids. The new designation of the SNP (rs1799971) based on the NCBI
Human Genome Assembly 36 is Asn102Asp (A355G) transition
(http://www.ncbi.nlm.nih.gov/SNP/).
This study has limitations. OPRM1 was defined (as in all other studies) according to
transcript variant NM_000914.2 (GenBank) containing four exons, encoding isoform
MOR-1 and spanning 79,864 bp. Therefore we selected markers to cover this region and up
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to 11.6 kb of the 5’ flanking region. However, another transcript variant that is publicly
available is MOR-10 (NM_001008503.1) (GenBank). MOR-10 lacks the 3' exon present in
MOR-1, but has an alternate downstream exon, as compared to variant MOR-1. Based on
this transcript the length of the gene is 207,558 bp spanning 127,694 bp downstream of the
3' end of transcript MOR-1. Exons 1,2,3 are identical in both transcript variants.
Accordingly, our markers and coverage are adequate in block 1 (covering up to 11.6 kb of
the 5’ flanking region and exon 1) but in block 2 (covering exon 3 and 4 based based on
MOR-1) the markers are not informative of the additional 127,694 bp downstream sequence
including the alternate downstream exon (175 bp) based on transcript variant MOR-10. In
addition, the statistical analysis was restricted to the three most common combinations of
haplotypes both in block 1 and block 2, omitting certain combinations of major haplotypes
(frequency ≥ 3%) and haplotypes with a frequency < 3%.
In this paper we attempted to evaluate the use of a single functional SNP against haplotypes
that did, and did not, contain that SNP. While it is beyond the scope of this paper, the issue
of a single SNP versus a haplotype approach could be generally raised. In general, haplotype
approaches are likely to be better when a single SNP has not been previously identified as
important or functional. This more exploratory approach, covering a larger genomic region,
could provide direction for further discovery that might include a more detailed evaluation
of whether any particular SNP in the haplotype carried a disproportionate weight of the
prediction or association. In the particular case of the OPRM1 gene, it appeared that this was
the case for the Asp40 SNP but we started from this premise and worked backward to arrive
at that conclusion. Other discovery might proceed in the other direction from haplotype
identification to specific SNP identification. It is also recognized that ancestry-specific
haplotype differences pose a particular challenge to this approach. A recent article on
alcohol expectancy effects in American Indians (Ehlers et al., 2008) that implicated OPRM1
SNP’s, other than that coding for Asp40, is an example of a number of these challenges.
In summary, in the present work, a haplotype-based approach was applied to identify effects
of unknown genetic variants in OPRM1 which might predict response to naltrexone
treatment. The ten SNPs genotyped were distributed in two haplotype blocks, a 44-kb block
covering up to 11.6 kb of the 5’regulatory region and exon 1, and a 28-kb block covering
exons 3 and 4, each represented by five major haplotypes. The only significant haplotype by
medication interaction found was in OPRM1 block 1 evidenced by the highest percent of
GCO among naltrexone-treated alcoholics with one copy of haplotype AGCCC, the single
haplotype carrying the Asp40 allele. No haplotype by medication interaction was observed
in block 2. Therefore, the haplotype-based approach confirms that the single locus predictive
of response to naltrexone treatment is Asn40Asp in exon 1. Contribution of any other
genetic variant of OPRM1 to interindividual variation in response to naltrexone treatment (at
least in terms of good clinical outcome) is not supported by our findings.
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Schematic (non-scaled) structure of the human μ opioid receptor gene (OPRM1) based on
the MOR-1 transcript variant (NM_000914.2). Positions of 10 SNPs genotyped and their
dbSNP IDs are also shown. Nucleotide +1 is the A of the ATG translation initiation codon,
the nucleotide 5’ to +1 is numbered −1.
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(A) Scaled schematic structure of OPRM1 (on line version is in color). The yellow (top) bar
represents the contig sequence spanning 20kb upstream and 10kb downstream of the 5’ and
3’ ends of the gene indicated by the green (lower) rectangle. The green vertical bars in the
rectangle indicate exons. (B) Linkage disequilibrium (LD) plot of 10 OPRM1 SNPs based
on 685 Caucasians in the COMBINE Study. The D’ value of each SNP pair is shown in the
squares. The numbers in the squares are D’x 100. Empty squares indicate D’ = 1. Squares
are colored bright red (dark grey) if the D’ value is high and the confidence in the value of
D’ is high as well. The first and the last markers in each block are also displayed on the
structure of OPRM1 to help the comparison between the two parts of the figure.
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Close correspondence of haplotypes in the COMBINE Study and HapMap and haplotype
grouping (on line version is in color). Alleles of markers (SNPs) genotyped in both datasets
are highlighted in green (bold). The first allele and second allele in the haplotypes are
depicted in blue (dark grey) and brown (light grey), respectively. The height of each
haplotype is proportional to the CEU haplotype frequency in HapMap. Haplotypes with a
frequency ≥ 3% are shown in both datasets. a). Block 1: The SNP (rs1799971) for
Asn40Asp(A118G) is highlighted in bold italics b). Block 2.
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Table 1
Demographics and pre-study drinking data of Caucasian participants who did not receive Combined
Behavioral Intervention and who had haplotype data for either the OPRM1 block 1 or block 2 haplotype
Placebo (n=160) Naltrexone (n=146)
Categorical variables, No. (%)
 Male 114 (71.3) 98 (67.1)
 Married 60 (37.5) 62 (42.5)
 Employed 121 (75.6) 108 (74.0)
 Years of education ≤ 12 46 (28.8) 38 (26.0)
 Current smoker 64 (40.0) 67 (45.9)
 GGT above normal limit 45 (28.1) 40 (27.4)
 CDT above normal limit 79 (49.4) 62 (42.5)
Continuous variables, mean (SD)
 Age, years 45.3 (10.51) 45.0 (10.98)
 Percent days abstinent (PDA)1 23.7 (25.09) 24.6 (25.06)
 Drinks per drinking day1 12.4 (7.08) 12.7 (8.51)
 Overall drinks per day1 9.3 (6.45) 9.4 (6.96)
 Heavy drinking days1 20.1 (8.31) 19.9 (8.59)
 Alcohol dependence score (ADS) 17.1 (7.33) 16.6 (8.14)
 OCDS score 26.2 (7.35) 25.3 (7.43)
 Drinking Consequences (DRINC) 49 (20.37) 46 (20.30)
 % CDT 3.6 (2.49) 3.2 (1.78)
 GGT IU/L 76.5 (152.7) 62.6 (75.76)
 Number of alcohol dependent symptoms from SCID 5.6 (1.26) 5.5 (1.28)
1
In the 30 days prior to randomization. Abbreviations: GGT, gamma-glutamyl transpeptidase; CDT, carbohydrate-deficient transferrin; OCD,
obsessive-compulsive drinking scale; SCID, structured clinical interview for DSM disorders
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Table 3
List of SNPs, their minor allele frequencies and HWE P values for distribution of genotypes at each locus
based on the whole cohort (915 subjects) and Caucasians (687 subjects)
Whole cohort Caucasians
NCBI dbSNP ID MAF1 HWE2 P value MAF HWE P value
rs1074287 0.278 0.427 0.254 0.442
rs1799971 0.125 0.434 0.126 0.485
rs510769 0.258 0.469 0.253 0.447
rs524731 0.198 0.085 0.196 0.158
rs1381376 0.156 0.625 0.159 0.536
rs2075572 0.436 0.254 0.427 0.471
rs540825 0.211 0.688 0.237 0.957
rs9322447 0.493 0.178 0.47 0.399
rs606148 0.082 0.635 0.086 0.612
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Table 4
Haplotypes in OPRM1 block 1 and their frequencies in COMBINE and HapMap. Haplotypes with a frequency
≥ 3% are shown
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Table 5
Haplotypes in OPRM1 block 2 and their frequencies in COMBINE and HapMap. Haplotypes with a frequency
≥ 3% are shown
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Table 6
Grouping of haplotypes for haplotype-based analyses based on relatedness and function in OPRM1 block 1
and block 2
Block 1 Block 2
Group A: AACCC Group A: CTGCG, GTACG, CTACG
Group B: AGCCC (single haplotype carrying Asp40) Group B: GAACA, GTAAA
Group C: GATCC, GATAC, GATAT
Group O: all the remaining haplotypes in block 1 (frequency: < 0.03) Group O: all the remaining haplotypes in block 2 (frequency < 0.03)
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